Bill > S04150

This bill amends existing New York state laws to expand the availability and definition of opioid reversal agents, primarily focusing on naloxone, a medication used to rapidly reverse opioid overdose. The legislation requires the Department of Health to make available any formulation and dosage of opioid reversal agents that have been approved by the Federal Food and Drug Administration (FDA), removing previous limitations that restricted options to only specific medications. The bill mandates the creation of a publicly accessible online directory that lists distributors of opioid reversal agents, including detailed information such as addresses, contact information, services offered, and availability of specific products. Additionally, the bill stipulates that the state will cover the cost of any FDA-approved nasal naloxone product, with any cost exceeding the highest-priced nasal naloxone product to be paid by the purchaser. This legislation aims to increase access to life-saving overdose prevention medications and provide more comprehensive information to the public about where these critical drugs can be obtained, ultimately supporting efforts to combat the opioid epidemic by making reversal agents more widely available and easier to access.

Health and Social Services

https://www.nysenate.gov/legislation/bills/2025/S4150